drugset

drugset / Trial / NCT00125307

Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis

NCT00125307 ↗

Phase 4 Completed 20 enrolled Chinese University of Hong Kong

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The investigators study the efficacy and safety of tacrolimus in the treatment of membranous nephritis secondary to systemic lupus erythematosus.

Timeline

Start: 2004-01
Primary completion: 2007-10
Completion: 2008-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tacrolimus	Small molecule	—	Oral

Indications